Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Class I Phosphatidylinositol 3-Kinases
/ genetics
ErbB Receptors
/ genetics
Female
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Nivolumab
/ therapeutic use
Progression-Free Survival
Proto-Oncogene Proteins p21(ras)
/ genetics
Retrospective Studies
Treatment Outcome
Tumor Suppressor Protein p53
/ genetics
Atezolizumab
EGFR
KRAS
MET
Nivolumab
Non-small cell lung cancer
PIK3CA
Pembrolizumab
STK11
TP53
Journal
Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
09
2019
accepted:
26
02
2020
pubmed:
9
4
2020
medline:
25
9
2020
entrez:
9
4
2020
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in NSCLC with other driver mutations. The increasing use of next-generation sequencing (NGS) leads to molecular findings that face the clinician with problems while choosing the best treatment. This study aims at analyzing response of NSCLC with driver mutations to immunotherapy. We retrospectively included 84 NSCLC patients diagnosed and treated at 2 German tertiary-care lung cancer centers using NGS and treatment with immunotherapy. Response to immunotherapy was analyzed in correlation to molecular findings. 51 patients harbored at least 1 driver mutation. PIK3CA, EGFR, and STK11 mutations did not respond to immunotherapy. KRAS, TP53, and MET exon 14 skipping mutations responded well. One patient with NF-1 mutation showed durable response. Molecular testing may be of use in guiding treatment decision making in NSCLC.
Identifiants
pubmed: 32268332
pii: 000506842
doi: 10.1159/000506842
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
KRAS protein, human
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Nivolumab
31YO63LBSN
atezolizumab
52CMI0WC3Y
pembrolizumab
DPT0O3T46P
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-298Informations de copyright
© 2020 S. Karger AG, Basel.